HLS Therapeutics Ownership

HLTRF Stock  USD 2.33  0.10  4.12%   
HLS Therapeutics has a total of 32.38 Million outstanding shares. Over half of HLS Therapeutics' outstanding shares are owned by outside corporations. These outside corporations are typically referred to as corporate investors that purchase positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Some institutional investors establish a significant position in pink sheets such as HLS Therapeutics in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of HLS Therapeutics, and when they decide to sell, the pink sheet will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in HLS Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

HLS Pink Sheet Ownership Analysis

About 64.0% of the company shares are owned by institutional investors. The company has price-to-book (P/B) ratio of 1.86. Some equities with similar Price to Book (P/B) outperform the market in the long run. HLS Therapeutics recorded a loss per share of 0.37. The entity last dividend was issued on the 30th of January 2023. HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. HLS Therapeutics Inc. was founded in 2018 and is headquartered in Etobicoke, Canada. Hls Therapeutics operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 92 people.The quote for HLS Therapeutics is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. To learn more about HLS Therapeutics call Gilbert Godin at 647 495 9000 or check out https://www.hlstherapeutics.com.

Currently Active Assets on Macroaxis

Other Information on Investing in HLS Pink Sheet

HLS Therapeutics financial ratios help investors to determine whether HLS Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in HLS with respect to the benefits of owning HLS Therapeutics security.